Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Accuray reports strong Q1 2023 earnings and focuses on global expansion

Accuray's Q1 2023 earnings call highlighted strong financial performance, with significant revenue growth and increased system orders. The company is focused on driving profitability expansion and expanding patient access to its technologies worldwide. While facing challenges in managing backlog and addressing performance in China, Accuray is actively pursuing opportunities for margin expansion and business growth.

Accuray delivers record Q2 performance, eyes growth opportunities ahead

Accuray's Q2 2023 performance highlighted record system deliveries and strong order growth, with a focus on radiation oncology services.
Despite challenges in revenue decline and backlog, strategic wins and progress in key regions position the company for future growth.
Opportunities lie in market expansion in the Americas, strategic wins in key regions, and advancements in China.
Maintaining growth momentum, addressing revenue challenges, and capitalizing on opportunities are key focus areas for Accuray.

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.

SUNNYVALE, Calif. , April 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2022, ended March 31, 2022, after the market close on April 27, 2022.

Accuray to Report Third Quarter Fiscal 2022 Financial Results on April 27, 2022

Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.

Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

Study Abstract Recognized as Best Clinical Abstract at 2022 Radiosurgical Society Meeting SUNNYVALE, Calif. , March 31, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that long-term follow-up data from a study of men and women with trigeminal neuralgia (TN) showed 72 percent continued to experience pain relief 10 years after receiving image-guided robotic radiosurgery treatments delivered with the CyberKnife ® System.

10-Year Data Shows Accuray CyberKnife® System Provides Long-Lasting Relief of the Excruciating Pain Caused by Trigeminal Neuralgia

Accuray's (ARAY) CyberKnife S7 System gets selected by the CARTI medical care team, thereby offering better cancer care in Arkansas via expanded access to advanced technology.

Accuray's (ARAY) CyberKnife S7 System Gets Chosen by CARTI

SUNNYVALE, Calif., March 8, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CARTI medical care team in Little Rock, Arkansas has treated the first patients in the state using the Accuray CyberKnife ® S7™ System.

CARTI Selects Accuray CyberKnife® S7™ System to Increase Access to Advanced Cancer Care for Patients in Rural Communities Throughout Arkansas

SUNNYVALE, Calif., Feb. 28, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the National Institute for Health and Care Excellence (NICE)* has endorsed the use of radiosurgery for trigeminal neuralgia (TN), strengthening the evidence for the company to market its CyberKnife® Treatment Delivery System for this indication in the United Kingdom.

NICE Endorses Radiosurgery Treatments for Trigeminal Neuralgia, Supporting Accuray CyberKnife® System Indications for Use

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?

Why Is Accuray (ARAY) Up 2.6% Since Last Earnings Report?

SUNNYVALE, Calif., Feb. 24, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Cowen 42nd Annual Health Care Conference taking place March 7-9, 2022.

Accuray to Participate in the Cowen 42nd Annual Health Care Conference

SUNNYVALE, Calif., Feb. 14, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Royal Brisbane and Women's Hospital (RBWH), the largest medical facility in Queensland, Australia, has selected two Radixact Systems with ClearRT™ helical fan-beam kVCT imaging and Synchrony ® artificial intelligence (AI)-driven four-dimensional (4D) dynamic delivery technology to expand access to potentially life-saving radiotherapy treatments to more patients.

Largest Hospital in Queensland, Australia Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies

Bit Digital, Inc

Moving Image Technologies

Reddit penny stocks for your February 2022 watch list. The post 3 Penny Stocks To Buy Now According To Reddit Traders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Buy Now According To Reddit Traders

SUNNYVALE, Calif., Feb. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a phase III, randomized controlled trial, TomoBreast, indicate post-surgery hypofractionated radiotherapy delivered with the TomoTherapy® System is superior to conventional radiotherapy in preserving long-term heart and lung functioning in women with early breast cancer.

Accuray TomoTherapy® Helical Radiotherapy System Helps Preserve Breast Cancer Patients' Long-term Heart and Lung Functionality

Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.

Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down

Accuray Incorporated (ARAY) CEO Joshua Levine on Q2 2022 Earnings Call Transcript

Accuray (ARAY) delivered earnings and revenue surprises of -100% and 10.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Break-Even Earnings for Q2

SUNNYVALE, Calif., Jan. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2022 ended December 31, 2021.

Accuray Reports Fiscal 2022 Second Quarter Financial Results

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Accuray (ARAY) Q2 Earnings Expected to Decline

SUNNYVALE, Calif., Jan. 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2022, ended December 31, 2021, after the market close on Wednesday, January 26, 2022.

Accuray to Report Second Quarter Fiscal 2022 Financial Results on January 26, 2022

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

Grab Holdings Ltd

Bionano Genomics

Innovid Corp

Thimble Point Acquisition Corp

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Buy-Rated Stocks Trading Under $10 With Huge 2022 New Year's Potential

Here is how Accuray (ARAY) and Assertio (ASRT) have performed compared to their sector so far this year.

Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?

Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.

Accuray's (ARAY) CyberKnife System Gets Shonin Approval

STERIS

Thermo Fisher Scientific

The Zacks Medical - Instruments industry is growing on COVID-support business gains. TMO, STE and ARAY are set to gain the most.

3 Top Medical Instruments Stocks to Counter Industry Headwinds

SUNNYVALE, Calif., Dec. 15, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received approval from the Japanese Ministry of Health, Labor and Welfare (Shonin) to market the CyberKnife® Robotic Radiosurgery System for the treatment of trigeminal neuralgia (TN) in Japan.

Accuray CyberKnife® Robotic Radiosurgery System Receives Shonin Approval to Treat Trigeminal Neuralgia, a Chronic Pain Condition Affecting a Facial Nerve

News for Accuray Stock (ARAY)